Last reviewed 2026-04-20 · How we verify

Mixtard® 30 TDS

Hospital Sultanah Aminah Johor Bahru · FDA-approved active Small molecule Quality 2/100

Mixtard® 30 TDS is a Small molecule drug developed by Hospital Sultanah Aminah Johor Bahru. It is currently FDA-approved.

At a glance

Generic name	Mixtard® 30 TDS
Sponsor	Hospital Sultanah Aminah Johor Bahru
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mixtard® 30 TDS CI brief — competitive landscape report
Mixtard® 30 TDS updates RSS · CI watch RSS
Hospital Sultanah Aminah Johor Bahru portfolio CI

Frequently asked questions about Mixtard® 30 TDS

What is Mixtard® 30 TDS?

Mixtard® 30 TDS is a Small molecule drug developed by Hospital Sultanah Aminah Johor Bahru.

Who makes Mixtard® 30 TDS?

Mixtard® 30 TDS is developed and marketed by Hospital Sultanah Aminah Johor Bahru (see full Hospital Sultanah Aminah Johor Bahru pipeline at /company/hospital-sultanah-aminah-johor-bahru).

What development phase is Mixtard® 30 TDS in?

Mixtard® 30 TDS is FDA-approved (marketed).

Manufacturer: Hospital Sultanah Aminah Johor Bahru — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing